GlassScriptPhysician profile
Wendy Bocaille
NPI 1457813503
$1,627.59
in general payments reported to CMS, 2019-2025
21 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.20 · 2023: $239 · 2024: $347 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.01 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $154.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $154.15 | 2024-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $149.57 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $146.60 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $146.03 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $97.70 | 2023-2025 | |
| Dexcom, INC. | $57.62 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $49.21 | 2025 | Gemtesa |
| Amphastar Pharmaceuticals, INC. | $47.83 | 2025 | |
| Tandem Diabetes Care, INC. | $40.48 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $38.91 | 2023-2025 | |
| Insmed, INC. | $36.29 | 2025 | Brinsupri, Arikayce |
| Xeris Pharmaceuticals, INC. | $35.44 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $34.25 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $26.50 | 2025 | Heplisav-B |
| Averitas Pharma INC. | $24.09 | 2024 | Qutenza |
| Abbott Laboratories | $20.99 | 2025 | Freestyle Libre 3 |
| Rhythm Pharmaceuticals, INC. | $20.14 | 2025 | Imcivree |
| Sanofi-Aventis U.S. LLC | $15.83 | 2025 | |
| Abbvie INC. | $13.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Bocaille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.